Population Study Reveals Most Effective Antipsychotic Strategies for First-Episode Schizophrenia
February 16, 2025
A recent population-based cohort study examined the effectiveness o...
Read More
Antipsychotic Polypharmacy on the Rise
December 16, 2024
Antipsychotic polypharmacy remains a common practice despite eviden...
Read More
Glutamatergic Modulation for Psychiatric Disorders
November 10, 2024
he science behind the role of glutamatergic neurotransmissions role...
Read More
Positive Results For Lumateperone in the Prevention of Relapse in Adult Patients with Schizophrenia
November 5, 2024
Positive results have been announced from phase III study evaluatin...
Read More
FDA Approves First Muscarinic Agonist for Schizophrenia
September 26, 2024
The U.S. Food and Drug Administration has approved xanomeline-tros...
Read More
Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
September 14, 2024
A new era of treatment strategies seems to be dawning with an incre...
Read More
Mortality Risk In Long-Acting Injectable Versus Oral Antipsychotics In Schizophrenia
September 9, 2024
Individuals with schizophrenia often struggle with consistently tak...
Read More
Long-Term Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia
July 26, 2024
A recent open-label extension study assessed the long-term outcomes...
Read More
Antipsychotics for Improved Negative Symptoms
May 19, 2024
Recent data indicates that upstream muscarinic modulation of downst...
Read More
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
May 13, 2024
Recent data indicates that upstream muscarinic modulation of downst...
Read More
Pharmacological Treatments for Psychotic Depression
March 22, 2024
Current treatment guidelines for psychotic depression recommend a c...
Read More
Science Update: Omega-3 Supplements May Reduce Schizotypal Personality Symptoms
March 9, 2024
A recent randomized controlled trial examined whether omega-3 fatty...
Read More